Carbon Revolution to Attend Sidoti Small-Cap Virtual Conference on March 13-14, 2024
GEELONG, Australia, March 08, 2024 (GLOBE NEWSWIRE) — Carbon Revolution plc (Nasdaq: CREV) (the “Company”), a Tier 1 OEM supplier […]
Arbutus to Participate in Two Upcoming Investor Conferences
WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive […]
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
Raised up to $140 million of non-dilutive non-recourse capital through a royalty-backed loan related to VABYSMO® from funds managed by […]
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
Leadership Changes Led by Appointment of Co-Founder Thomas Jensen as Interim CEO and Jeremy Graff, Ph.D., former Eli Lilly Executive, […]
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder
TEL AVIV, Israel, March 08, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical […]
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
Published results show EYLEA HD with extended 12- or 16-week dosing regimens demonstrated non-inferior vision gains to standard of care […]
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
HAMPTON, N.J., March 08, 2024 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a […]
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
Data adds to increasing body of evidence supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach […]
Augmedix to Announce Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024
SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) — Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading, ambient medical documentation […]
Bio-Path Holdings Reports Full Year 2023 Financial Results
HOUSTON, March 08, 2024 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery […]
